GIP receptor
Records checked
Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk
Qualified clinical review None on record
3 of the 17 compounds in scope are recorded as acting at the GIP receptor. 0 of them record it as their only target; the rest carry a multi-receptor profile.
Definition
The glucose-dependent insulinotropic polypeptide receptor is the second incretin receptor. Tirzepatide is reported in its 2021 Lancet trial report as a dual GIP and GLP-1 receptor agonist.[1]
Also written as glucose-dependent insulinotropic polypeptide receptor, GIPR.
Recorded on the compound records as: GIP receptor.
Compounds in scope recorded at this target
| Compound | Class | Other targets recorded | Targets | Records | Human trial model | Phase 3 | Index state |
|---|---|---|---|---|---|---|---|
| Maridebart cafraglutide | Incretin receptor agonists | GLP-1 receptor | 2 | 5 | 2 | 0 | Withheld |
| Retatrutide | Incretin receptor agonists | GLP-1 receptor, Glucagon receptor | 3 | 12 | 3 | 1 | Withheld |
| Tirzepatide | Incretin receptor agonists | GLP-1 receptor | 2 | 12 | 10 | 7 | Withheld |
Record counts are of records this corpus carries, not of the literature. A larger count reflects how long and how heavily a compound has been indexed. It is not a measure of anything about the compound, and the rows are in alphabetical order so the table cannot be read as a ranking.
What else these compounds are recorded at
- GLP-1 receptor: 3 of the 3 also recorded at the GLP-1 receptor
- Glucagon receptor: 1 of the 3 also recorded at the Glucagon receptor
Where this page sits
- Every receptor target in scope
- The glossary of receptor terms
- Coverage by endpoint, across all compounds in scope